CASE OF USING THE INHIBITOR OF INTERLEUKIN 1 CANACINUMAB IN PATIENTS WITH AUTO INFLAMMATORY DISEASES

Interleukin 1 (IL 1) is the main mediator for many auto inflammatory diseases (AID). Cryopyrin-associated periodic syndromes (CAPS) became the first diseases, for which the efficacy of IL 1 inhibitors was shown with a high degree of evidence. Canacinumb (totally human monoclonal antibodies to IL 1 is registered in Russia since 2011 for treating CAPS. At the moment research is being conducted to evaluate the efficacy and tolerance to IL 1 inhibitors in patients with other AIDs. The accumulated experience and scarce randomized
controlled studies demonstrate a successful usage of IL 1 inhibitors in colchicine-resistant patients with family Mediterranean fever with the cupping of inflammation attacks, reducing the acute phase activity and also in patients with other monogenic (TRAPS, HIDS and others) and multifactorial pathologies (systemic juvenile arthritis, Stilk disease in adults, gout etc.). Using the IL 1 inhibitors, especially canacinumab, in patients with different AIDs has shown good tolerance and a high efficacy in all patients with no correlation to the age, according to Russian and world research. Thus, canacinumab, thanks to its therapeutic abilities, has broad perspectives in terms of lightening the disease course, improving survival, life quality and the overall prognosis.

1. Federici S., Gattorno M. A practical approach to the diagnosis of autoinflammatory diseases in childhood. Best Practice and Research Clin. Rheumatol. 2014; 28: 263–276.

2. Fietta P. Autoinflammatory disease: the hereditary periodic fever syndromes. Acta Biol. Ateneo Parmense. 2004; 75: 92–99.

3. Kuz'mina N.N., Salugina S.O., Fedorov E.S. Autovospalitel'nye zabolevaniya i sindromy u detei. Uchebno–metodicheskoe posobie [Autoinflammatory Diseases and Syndromes in Children. Textbook]. Moscow, IMA–PRESS, 2012. 104 p.

4. Dinarello C. Bloking IL–1 in systemic inflammation. JEM. 2005; 201: 1355–1359.

5. Simon A., van der Meer J.W.S. Pathogenesis of familial periodic fever syndromes or hereditary inflammatory syndromes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007; 292: 86–98.

6. Goldbach–Mansky R., Kastner D.L. Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implication for common illnesses. J. Allergy Clin. Immunol. 2009; 124: 1141–1151.

7. Dinarello C. A Signal for the Caspase–1 Inflammasome Free of TLR. Immun. 2007; 26: 383–385.

8. Drenth J.P.H., van der Meer W.M. The Inflammasome A Linebacker of Innate Defense. N. Engl. J. Med. 2006; 355: 730–732.

9. Federici S., Martini A., Gattorno M. The central role of anti-IL-1 blockade in the treatment of monogenic and multifactorial autoinflammatory diseases. Frontiers un Immunology. 2013; 4: 351.

10. Gattorno M. Autoinflammatory diseases in children. Voprosy sovremennoi pediatrii = Current pediatrics. 2014; 13: 55–64.

11. Ter Haar N., Lachmann H.J., Ozen S., Woo P., Uziel Y., Modesto C., Kone–Paut I. Treatment of autoinflammatory disease: results from the Eurofever Registry and a literature review. Ann. Rheum Dis. 2013; 72: 678–685.

12. URL: http://fmf.igh.cnrs.fr/ISSAID/infevers/index.php (available: 14.04.2015).

13. Kuijk L.M., Hoffman H.L., Neven B., Frenkel J. Episodic Autoinflammatory Disorders in Children. In Handbook of Systemic Autoimmune Disease. Pediatrics in Systemic Autoimmune Disease. Eds. R. Cimas, Lehman T. New York: Elsevier Saunders. 2008. V. 6. P. 119–135.

14. Feldman J. Prieur A.M., Quartier P., Berquin P., Certain S., Cortis E., Teillac–Hamel D., Fischer A., de Saint Basile G. Chronic infantile neurological cutaneouse and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonucleare cells and chondrocytes. Am. J. Hum. Genet. 2002; 71: 198–203.

15. Hoffman H.M.. Mueller J.L., Broide D.H., Wanderer A.A., Kolodner R.D. Mutation of a new gene encoding a putative pyrine like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nat. Genet. 2001; 29: 915–921.

16. Cuisset L., Jeru I., Dumont B., Fabre A., Cochet E., Bozec J., Delpech V., Amselem S., Touitou I., and the French CAPS study group. Mutation in the autoinflammatory cryopyrin associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann. Rheum. Dis. 2011; 70: 495–499.

17. Barron K., Athreya B., Kastner D. Periodic fever syndromes and other inherited autoinflammatory diseases. In: Textbook of pediatric rheumatology. Ed. Cassidy J.T. New York: Elsevier Saunders. 2011. Р. 642–660.

18. Kitley J.L., Lachmann H.J., Pinto A., Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology. 2010; 2074 (16): 1267–1270.

19. Yu J.R. and Leslie K. S. Cryopyrin Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response. Curr. Allergy Asthma Rep. 2011; 11 (1): 12–20.

20. Federico G., Rigante D., Pugliese A.L., Ranno O., Catania S., Stabile A. Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand. J. Rheumatol. 2003; 32: 312–314.

21. Kuemmerle–Deschner J., Haug I. Canakinumab in patients with cryopyrin associated periodic syndrome: an update for clinicians. Ther. Adv. Musculoskel Dis. 2013; 5 (6): 315–319.

22. Toker O., Hashkes P.J. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin associated periodic syndrome (CAPS). Biologics: Targets &Therapy. 2010; 4: 131–138.

23. Bonner J., Lloyd P., Lowe P., Lowe P., Golor G. PK/PD, safety and tolerability of a human anti–IL–1β monoclonal antibody (ACZ885) in healthy subjects. Annual Congress of the European Respiratory Society. 2006. Abstract 748.

24. Lachmann H., Kone–Paut I., Kuemmerle–Deschner G.B., Leslie K.S., Hachulla E., Quartier P., Gitton X., Widmer A. Use of canakinumab in the cryopyrin associated periodic syndrome. N. Engl. J. Med. 2009; 360: 2416–2425.

25. Kuemmerle–Deschner J.B., Hachulla E., Gartwright R., Hawkins P.N., Tran T.A., Bader–Meunier B., Hoyer J., Gattorno M., Gul A., Smith J., Leslie K.S., Jiménez S., Morell–Dubois S., Davis N., Patel N., Widmer A., Preiss R., Lachmann H.J. Two year results from an open label, multicentre, phase III study evaluating the safety and efficacy of Canakinumab in pts with cryopyrin associated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 2011; 70 (12): 2095–2102.

26. Goldbach–Mansky R., Sibley C., Felix S., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I. Efficacy and safety of canacinumab in patients with NOMID/CINCA. Ann. Rheum. Dis. 2012; 71 (suppl.3): 291.

27. Caorsi R., Lepore L., Zulian F., Alessio M., Stabile A., Insalaco A., Finetti M., Battagliese A., Martini G., Bibalo C., Martini A., Gattorno M. The schedule of administration of Canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res. Ther. 2013; 15 (1): 33.

28. Hoffman H., Kuemmerle–Deschner J., Hawkins P. et al. Safety of canacinumab in a large cohort of patients with cryopirin associated periodic syndrome: results from the confident registry. Arthritis Rheum. 2012; 64 (10): 78.

29. Galon J., Aksentijevich I., Mc Dermott F., O`Shea J.J., Kastner D.L. TNFRSF1A mutations and autoinflammatory syndromes. Curr. Opin. Immunol. 2000; 12: 479–486.

30. Williamson L.M., Hull D., Mehta R., Reeves W.G., Robinson B.H., Toghill P.J. Familial Hibernian fever. Q. J. Med. 1982; 51: 469–480.

31. Lachmann H.J., Papa R., Gerhold K., Obici L., Touitou I., Cantarini L., Frenkel J., Anton J., Kone–Paut I., Cattalini M., Bader–Meunier B., Insalaco A., Hentgen V., Merino R., Modesto C., Toplak N., Berendes R., Oze, S., Cimaz R., Jansson A., Brogan P.T., Hawkins P.N., Ruperto N., Martini A., Woo P., Gattorno M. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann. Rheum. Dis. 2014; 73: 2160–2167. doi: 10.1136/annrheumdis-2013-204184368.

32. Aksentijevich I., Galon J., Soares M., Mansfield E., Hull K., Oh H.H., Goldbach–Mansky R. The tumor necrosis factor receptor associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am. J. Hum. Genet. 2001; 692: 301–314.

33. Drenth G., van der Meer G.W. Hereditary Periodic fever. New Engl. J. of med. 2001: 345: 1748–1757.

34. Jesus A.A., Goldbach–Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin. Immunol. 2013; 147 (3): 155–174. doi:10.1016/j.clim.2013.03.016

35. Cantarini L., Lucherini O.M., Muscari I., Frediani B., Galeazzi M., Brizi M.G., Simonini G, Cimaz R. Tumor necrosis factor receptor — associated syndrome (TRAPS): State of the art and future perspectives. Autoimmunity Rev. 2012; 12: 38–43. DOI 10.1016/j.autrev.2012.07.020

36. Aganna E., Hammond L., Hawkins P.N. et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Art. Rheum. 2003; 48: 2632–2644.

37. Aksentijevich I., Galon J., Soares M., Mansfield E., Hull K., Oh H.H., Goldbach–Mansky R. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am. J. Hum. Genet. 2001; 692: 301–314.

38. Caso F., Rigante D., Vitale A., Lucherini O.M., Costa L., Atteno M., Compagnone A., Caso P., Frediani B., Galeazzi M., Punzi L., Cantarini L. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Intern. J. of Rheum. 2013; 2013: 513782. DOI 10.1155/2013/513782.

39. Dode C., Cuisset L., Delpech M., Grateau G. TNFRSF1A associated periodic syndrome (TRAPS), Muckle–Wells syndrome (MWS) and renal amyloidosis. J. Nephrol. 2003; 16: 435–437.

40. Hull K.M., Drewe E., Aksentijevich I., Singh H.K., Wong K., McDermott E.M., Dean J., Powell R.J., Kastner D.L. The TNF receptor associated autoinflammatory syndrome (TRAPS): emerging concepts of an autoinflammatoty disorders. Medicine (Baltimore). 2002; 81: 349–368.

41. Bulua A.C., Mogul D.B., Aksentijevich I., Singh H., He D.Y., Muenz L.R., Ward M.M., Yarboro C.H., Kastner D.L., Siegel R.M., Hull K.M. Efficacy of Etanercept in the Tumor Necrosis Factor Receptor — Associated Periodic Syndrome: A Prospective Open Label, Dose Escalation Study. Artritis Rheum. 2012; 64: 908–913. doi: 10.1002/art.33416

42. Caorsi R., Federici S., Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmunity Rev.2012; 12: 81–86.

43. Gattorno M., Obici L., Meini A., Tormey V., Abrams K., Davis N., Andrews C., Lachmann H.J. Efficacy and safety of Canakinumab in patients with TNF receptor associated periodic syndrome. Arthritis Rheum. 2012; 64 (10): 322.

44. Brizi M.G., Galeazzi M., Lucherini O.M., Cantarini L., Cimaz R. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canacinumab. Ann. of Intern. Med. 2012; 156 (12): 907–908.